Antibiotic complications during the treatment of Mycobacterium ulcerans disease in Australian patients
- PMID: 28585259
- DOI: 10.1111/imj.13511
Antibiotic complications during the treatment of Mycobacterium ulcerans disease in Australian patients
Abstract
Background: Antibiotics are the recommended first-line treatment for Mycobacterium ulcerans disease. Antibiotic toxicity is common in Australian patients, yet antibiotic complication rates and their risk factors have not been determined.
Aim: To determine the incidence rate and risk factors for antibiotic toxicity in Australian patients treated for M. ulcerans disease.
Methods: An analysis of severe antibiotic complications was performed using data from a prospective cohort of M. ulcerans cases managed at Barwon Health from 1 January 1998 to 30 June 2016. A severe antibiotic complication was defined as an antibiotic adverse event that required its cessation. Antibiotic complication rates and their associations were assessed using a Poisson regression model.
Results: A total of 337 patients was included; 184 (54.6%) males and median age 57 years (interquartile range (IQR) 36-73 years). Median antibiotic treatment duration was 56 days (IQR 49-76 days). Seventy-five (22.2%) patients experienced severe antibiotic complications after a median 28 days (IQR 17-45 days) at a rate of 141.53 per 100 person-years (95% confidence interval (CI) 112.86-177.47). Eleven (14.7%) patients required hospitalisation. Compared with rifampicin/clarithromycin combinations, severe complication rates were not increased for rifampicin/ciprofloxacin (rate ratio (RR) 1.49, 95% CI 0.89-2.50, P = 0.13) or rifampicin/moxifloxacin (RR 2.54, 95% CI 0.76-8.50, P = 0.13) combinations, but were significantly increased for 'other' combinations (RR 2.53, 95% CI 1.13-5.68, P = 0.03). In a multivariable analysis, severe complication rates were significantly increased with reduced estimated glomerular filtration rates (EGFR) (adjusted rate ratio (aRR) 2.65, 95% CI 1.24-5.65 for EGFR 60-89 mL/min and aRR 1.31, 95% CI 0.49-3.53 for EGFR 0-59 mL/min compared with EGFR ≥90 mL/min, P < 0.01) and female gender (aRR 2.15, 95% CI 1.38-3.30, P < 0.01).
Conclusions: Severe antibiotic complications during M. ulcerans treatment are high with increased rates independently associated with reduced renal function and female gender.
Keywords: Mycobacterium ulcerans; Australia; adverse effect; antibiotic treatment; complication.
© 2017 Royal Australasian College of Physicians.
Similar articles
-
Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus statement.Med J Aust. 2025 Jun 16;222(11):571-578. doi: 10.5694/mja2.52591. Epub 2025 Feb 23. Med J Aust. 2025. PMID: 39987502 Free PMC article.
-
Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.PLoS Negl Trop Dis. 2012 Jan;6(1):e1473. doi: 10.1371/journal.pntd.0001473. Epub 2012 Jan 17. PLoS Negl Trop Dis. 2012. PMID: 22272368 Free PMC article.
-
Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections.BMC Infect Dis. 2013 Sep 5;13:416. doi: 10.1186/1471-2334-13-416. BMC Infect Dis. 2013. PMID: 24007371 Free PMC article.
-
Mycobacterium ulcerans in the Elderly: More Severe Disease and Suboptimal Outcomes.PLoS Negl Trop Dis. 2015 Dec 2;9(12):e0004253. doi: 10.1371/journal.pntd.0004253. eCollection 2015 Dec. PLoS Negl Trop Dis. 2015. PMID: 26630648 Free PMC article.
-
Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection).Curr Opin Infect Dis. 2010 Oct;23(5):445-55. doi: 10.1097/QCO.0b013e32833c2209. Curr Opin Infect Dis. 2010. PMID: 20581668 Review.
Cited by
-
Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus statement.Med J Aust. 2025 Jun 16;222(11):571-578. doi: 10.5694/mja2.52591. Epub 2025 Feb 23. Med J Aust. 2025. PMID: 39987502 Free PMC article.
-
A human model of Buruli ulcer: Provisional protocol for a Mycobacterium ulcerans controlled human infection study.Wellcome Open Res. 2024 Oct 21;9:488. doi: 10.12688/wellcomeopenres.22719.2. eCollection 2024. Wellcome Open Res. 2024. PMID: 39386965 Free PMC article.
-
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug. PLoS Negl Trop Dis. 2018. PMID: 30102705 Free PMC article.
-
Mycobacterium Ulcerans Ulcer: Current Trends in Antimicrobial Management and Reconstructive Surgical Strategies.Life (Basel). 2025 Jul 13;15(7):1096. doi: 10.3390/life15071096. Life (Basel). 2025. PMID: 40724599 Free PMC article. Review.
-
Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00426-19. doi: 10.1128/AAC.00426-19. Print 2019 Jul. Antimicrob Agents Chemother. 2019. PMID: 31036687 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous